Log in

NASDAQ:PULM - Pulmatrix Stock Price, Forecast & News

$1.54
-0.04 (-2.53 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$1.52
Now: $1.54
$1.61
50-Day Range
$1.42
MA: $1.57
$1.82
52-Week Range
$0.61
Now: $1.54
$3.01
Volume226,727 shs
Average Volume512,498 shs
Market Capitalization$30.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$2.32 per share

Profitability

Net Income$-20,560,000.00

Miscellaneous

Employees22
Market Cap$30.80 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.


Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Pulmatrix shares reverse split on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) issued its quarterly earnings data on Friday, November, 1st. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.16. The biotechnology company had revenue of $1.41 million for the quarter. View Pulmatrix's Earnings History.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Pulmatrix.

What price target have analysts set for PULM?

1 equities research analysts have issued twelve-month price targets for Pulmatrix's shares. Their forecasts range from $10.00 to $10.00. On average, they expect Pulmatrix's stock price to reach $10.00 in the next year. This suggests a possible upside of 549.4% from the stock's current price. View Analyst Price Targets for Pulmatrix.

What is the consensus analysts' recommendation for Pulmatrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.

Has Pulmatrix been receiving favorable news coverage?

News coverage about PULM stock has trended negative this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pulmatrix earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Pulmatrix.

Are investors shorting Pulmatrix?

Pulmatrix saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 925,100 shares, an increase of 323.2% from the January 15th total of 218,600 shares. Based on an average trading volume of 917,000 shares, the days-to-cover ratio is currently 1.0 days. Approximately 4.8% of the shares of the stock are sold short. View Pulmatrix's Current Options Chain.

Who are some of Pulmatrix's key competitors?

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Verastem (VSTM), Cronos Group (CRON), Inovio Pharmaceuticals (INO), Neovasc (NVCN), Biopharmx (BPMX), Evoke Pharma (EVOK), TherapeuticsMD (TXMD), Cara Therapeutics (CARA) and Second Sight Medical Products (EYES).

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the folowing people:
  • Dr. Robert W. Clarke, CEO, Pres & Director (Age 50)
  • Mr. William E. Duke Jr., CFO, Treasurer & Sec. (Age 47)
  • Dr. James M. Roach, Consultant (Age 59)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 70)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 58)

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.22%) and Acadian Asset Management LLC (0.48%). View Institutional Ownership Trends for Pulmatrix.

Which institutional investors are buying Pulmatrix stock?

PULM stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Acadian Asset Management LLC. View Insider Buying and Selling for Pulmatrix.

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $1.54.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $30.80 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-20,560,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.View Additional Information About Pulmatrix.

What is Pulmatrix's official website?

The official website for Pulmatrix is http://www.pulmatrix.com/.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]


MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  300
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel